Safety and Pharmacokinetics of Exebacase in an Infant With Disseminated Staphylococcus aureus Infection.

Abstract

Exebacase, an antistaphylococcal lysin produced from a bacteriophage-encoded gene, is a promising adjunctive therapy for severe methicillin-resistant Staphylococcus aureus infections. We describe the first infant to receive exebacase, dosing, and pharmacokinetics. Exebacase may be safe and efficacious in children; however, further clinical trials are needed to optimize dosing.

• Authors: Ganga S Moorthy, Rachel G Greenberg, Chi D Hornik, Cara Cassino, Parviz Ghahramani, Karan R Kumar, Vance G Fowler, Michael Cohen-Wolkowiez
• Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (Clin Infect Dis) Vol. 75 Issue 2 Pg. 338-341 (08 25 2022) ISSN: 1537-6591 [Electronic] United States
• PMID: 34894129 (Publication Type: Case Reports, Journal Article, Research Support, N.I.H., Extramural)
• Copyright: © The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: [email protected].

Chemical References

• Anti-Bacterial Agents
• exebacase
• Endopeptidases

Topics

• Anti-Bacterial Agents (therapeutic use)
• Child
• Endopeptidases
• Humans
• Infant
• Methicillin-Resistant Staphylococcus aureus
• Staphylococcal Infections (drug therapy)
• Staphylococcus aureus